Kuwabara Satoshi, Dispenzieri Angela, Arimura Kimiyoshi, Misawa Sonoko
Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana , Chuo-Ku, Chiba, Japan, 260-8670.
Cochrane Database Syst Rev. 2008 Oct 8(4):CD006828. doi: 10.1002/14651858.CD006828.pub2.
POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome is a rare cause of demyelinating and axonal mixed neuropathy with multiorgan involvement and monoclonal plasma cell-proliferative disorder. The pathogenesis of POEMS syndrome is not well understood, but overproduction of vascular endothelial growth factor (VEGF), probably secreted by plasmacytomas, is likely to be responsible for most of the characteristic symptoms. POEMS syndrome is a potentially fatal disease, and patients' quality of life deteriorates because of progressive neuropathy, massive pleural effusion or ascites, or thromboembolic events. There is a need for efficacious therapy to improve prognosis.
To provide the best available evidence from randomised controlled trials on treatment for POEMS syndrome.
We searched the Cochrane Neuromuscular Disease Group Trials Register (March 2008), MEDLINE (from January 1966 to March 2008), EMBASE (from January 1980 to March 2008) and CINAHL (from January 1982 to March 2008) for randomized controlled trials, quasi-randomized trials, historically controlled studies, and trials with concurrent controls. We adapted this strategy to search MEDLINE from 1966 and EMBASE from 1980 for comparative cohort studies, case-control studies and trials, and case series.
All randomized and quasi-randomized controlled trials, and non-randomized controlled studies were sought. Since we discovered no such clinical trials , we assessed and summarized all retrospective case series including five or more patients in the 'Discussion' section.
Two authors independently reviewed and extracted details of all potentially relevant trials with any treatment for POEMS syndrome. We then collated and summarized information on the outcome.
We found no randomized or non-randomized prospective controlled trials of treatment for POEMS syndrome. We summarized the results of retrospective case series containing five or more patients in the Discussion section.
AUTHORS' CONCLUSIONS: There are no randomized or quasi-randomized controlled clinical trials of treatment for POEMS syndrome on which to base practice.
POEMS(多发性神经病、脏器肿大、内分泌病、M蛋白和皮肤改变)综合征是脱髓鞘和轴索性混合性神经病的罕见病因,伴有多器官受累及单克隆浆细胞增殖性疾病。POEMS综合征的发病机制尚不完全清楚,但血管内皮生长因子(VEGF)过度产生,可能由浆细胞瘤分泌,可能是导致大多数特征性症状的原因。POEMS综合征是一种潜在的致命疾病,由于进行性神经病、大量胸腔积液或腹水或血栓栓塞事件,患者的生活质量会恶化。需要有效的治疗方法来改善预后。
提供关于POEMS综合征治疗的随机对照试验的最佳现有证据。
我们检索了Cochrane神经肌肉疾病组试验注册库(2008年3月)、MEDLINE(1966年1月至2008年3月)、EMBASE(1980年1月至2008年3月)和CINAHL(1982年1月至2008年3月),以查找随机对照试验、半随机试验、历史对照研究以及同期对照试验。我们调整了该策略,检索1966年以来的MEDLINE和1980年以来的EMBASE,以查找比较队列研究、病例对照研究和试验以及病例系列。
查找所有随机和半随机对照试验以及非随机对照研究。由于我们未发现此类临床试验,因此在“讨论”部分评估并总结了所有包括五名或更多患者的回顾性病例系列。
两位作者独立审查并提取了所有针对POEMS综合征进行任何治疗的潜在相关试验的详细信息。然后,我们整理并总结了关于结果的信息。
我们未发现针对POEMS综合征治疗的随机或非随机前瞻性对照试验。我们在“讨论”部分总结了包含五名或更多患者的回顾性病例系列的结果。
目前尚无用于指导POEMS综合征治疗实践的随机或半随机对照临床试验。